FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

Season 8 Episode 45  ·  May 15, 2023, 07:20 PM

Headliner
Share
Subscribe

Dr Horwitz discusses the FDA approval of omidubicel in patients with blood cancers, key efficacy and safety data from the pivotal phase 3 trial, and the benefits omidubicel provides beyond improved neutrophil engraftment.

Share
Subscribe
Next
Oncology Professionals Explain the Nuances of Career-Building Mentorship and Self-Advocacy
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air